Stocks / Stock overview

Intuitive Surgical Inc (ISRG)

$443.85+3.67%Aft $444.50 (+0.15%)Market cap $156.80B

NasdaqGS · Price as of · Nasdaq Real Time Price

Stock Scorer
A75/100
  • Profitability20/20

    Profitable and growing: $2.96B net income over the last four reported quarters, up from $2.75B the year before.

  • Insider buying vs selling11/20

    Insiders are sellers only: 32 sells worth $7.6M, no open-market buys, across the last 20 Form 4s. Routine executive selling is common, so this is only a mild negative. Separately, 1 new 5%+ stake disclosure (13D/13G) hit in the last 6 months, which is big-money accumulation.

  • Dilution and offerings15/15

    Share count down 2.2% in a year with no new offering filings. The company is buying back stock.

See the full breakdown
Analyst consensus
Buy$480.13
  • Analysts30
  • Implied upside+8.2%
  • Target range$324.00 to $685.00
Analyst estimates are opinions, not forecasts of what the stock will do.
Source: Yahoo Finance consensus, retrieved
Next earnings
January 21, 2027in 91 days
  • EPS expected$2.96 +17%
  • A year ago$2.53
  • Revenue expected$3.23B +13%
  • Estimate range$2.85 to $3.04
Consensus of 23 analysts for the quarter ending December 31, 2026. Beat the estimate in all four of the last four quarters. Estimates are what Wall Street expects, not our forecast.
Source: Yahoo Finance earnings calendar
ISRG past month+11.4%
ISRG closed at $443.85 on Oct 22, up 11.4% since Sep 23.$443.85$373.66Sep 23Oct 22
Close 20-day average 50-day average 200-day average

ISRG closed at $443.85 on Oct 22, up 11.4% since Sep 23. Chart read: price above both the 50-day and 200-day moving averages; the 50-day is below the 200-day (downtrend structure); trading at 43% of the 52-week range ($332.02 to $592.85).

Insider buying and selling at Intuitive Surgical Inc (ISRG)

Source: SEC Form 4 filingsLatest filed

The most recent Form 4 on record for Intuitive Surgical Inc (ISRG) is January 27, 2026, when Gary S Guthart, Director, sold $14.5M of stock. That sale ran under a pre-arranged 10b5-1 plan, so it was scheduled ahead of time rather than decided that week.

InsiderActionValueDateType
Gary S Guthart · DirectorSell$14.5MJanuary 27, 2026Routine
Gary S Guthart · Executive Chair of the Board oSell$13.0MDecember 1, 2025Routine
Gary S Guthart · Executive Chair of the Board oSell$17.3MOctober 24, 2025Routine
David J. Rosa · Chief Executive Officer (CEO)Sell$13.4MOctober 24, 2025Routine
Gary S Guthart · Executive Chair of the Board oSell$13.9MAugust 29, 2025Routine
All insider activity

Filed notices to sell

Source: SEC Form 144 noticesLatest filed

A Form 144 is filed beforean insider sells restricted stock. The Form 4 reporting the completed trade isn't due until two business days after the sale, so these land first. They are intentions, not transactions.

InsiderValueFiledStatusType
Widman Fredrik · Officer$823,153September 15, 2026ExecutedRoutine
Brosius Mark · Officer$254,490September 8, 2026Not yet reportedRoutine
GUTHART GARY S · Director$7.9MAugust 11, 2026ExecutedRoutine
Ladd Amy L · Director$178,798August 10, 2026Not yet reportedRoutine
LOEB GARY · Officer$151,524August 10, 2026Not yet reportedRoutine
All filed notices

How Congress has done in ISRG

Source: AIStockWire, scored from STOCK Act disclosures against daily price historyGenerated

Every purchase of ISRG disclosed by a member of Congress in the last 5 years, scored over the 12 months after the trade date against SPY over the same window.

MeasureISRGSPY
Median 12-month return after purchase+20.1%+21.4%
Median difference vs SPY+1.2%—
Purchases that beat SPY8 of 16 (50%)—
Members who bought8—

Most frequent buyers: Greg Landsman (4), Josh Gottheimer (4), Daniel Goldman (2), Lisa McClain (2), Gil Cisneros (1).

These are not returns anyone actually earned. Disclosures report a dollar bracket and no share count, so every purchase is counted once and weighted equally, and sales are not matched back to the buys that opened them. 4 of the 16 purchases are disclosed as a spouse's or dependent's rather than the member's own. Purchases from the last 12 months are excluded because their window has not closed yet.

Congress trades in ISRG

Source: STOCK Act disclosures filed with the House and SenateLatest disclosed

DateMemberActionAmount
2026-08-07Michael McCaul TXPurchase$15,001 - $50,000
All congress trades

SEC filings

Source: SEC EDGARLatest filed

FormFiledDescription
10-QOctober 21, 202610-Q
8-KOctober 20, 20268-K
4October 13, 2026PRIMARY DOCUMENT
4October 13, 2026PRIMARY DOCUMENT
4September 16, 2026PRIMARY DOCUMENT
144September 15, 2026View on EDGAR
4September 11, 2026PRIMARY DOCUMENT
4September 9, 2026PRIMARY DOCUMENT
All SEC filings

Articles that mention Intuitive Surgical without it being the main subject.

The FCC moved to ban Chinese robots. Agility Robotics (CCXI) rose 12% in half an hour while the humanoid ETF (KOID) fell.
News

The FCC moved to ban Chinese robots. Agility Robotics (CCXI) rose 12% in half an hour while the humanoid ETF (KOID) fell.

The FCC moved July 28 to bar new Chinese humanoid and quadruped robots, plus connected power inverters, from the US market. Four small robotics names did all the moving: RoboStrategy (BOT) closed up 17.6% and Churchill Capital XI (CCXI) rose 12.3% in the half hour after the headline. Teradyne then jumped after hours on earnings. The robotics ETFs closed lower.

Jul 28, 2026
All seven Magnificent Seven stocks fell today. Here's where that money actually went (July 23, 2026)
News

All seven Magnificent Seven stocks fell today. Here's where that money actually went (July 23, 2026)

All seven Magnificent Seven stocks were red by late morning Thursday, led by Tesla's 14% drop on an earnings miss and Alphabet's close-to-7% slide despite beating estimates, on another capex raise. Amazon and Meta sold off too ahead of next week's reports. The money didn't just leave, it rotated: into defense on Lockheed's earnings beat, and out of quantum, SaaS and space.

Jul 23, 2026
The Close, July 14: IBM lost a quarter of its value, and SK Hynix's Nasdaq stock jumped 27%
News

The Close, July 14: IBM lost a quarter of its value, and SK Hynix's Nasdaq stock jumped 27%

IBM lost about a quarter of its value in a single session after a weak preliminary report, and the damage spread across enterprise software. SK Hynix's brand-new Nasdaq stock went the other way, jumping 27% on a day chips broadly rallied.

Jul 14, 2026
See all 6 ISRG articles

Frequently asked questions

When does ISRG report earnings?

Intuitive Surgical Inc (ISRG) is scheduled to report quarterly results on January 21, 2027. The 23-analyst consensus is $2.96 per share on revenue of $3.23B for the quarter ending December 31, 2026, against $2.53 and $2.87B a year earlier. It has beaten the consensus EPS estimate in all four of the last four quarters.

What do analysts expect for ISRG?

30 analysts cover Intuitive Surgical Inc (ISRG). The consensus rating is Buy. The average price target is $480.13, in a range of $324.00 to $685.00.

Are insiders buying or selling ISRG?

We track Form 4 filings for Intuitive Surgical Inc (ISRG). The activity listed on this page shows 5 qualifying sales. Each row is labelled Routine when the filer declared a pre-arranged 10b5-1 plan, Tax withholding when shares were sold automatically to cover the tax on a vest, or Own call when neither applies.

Has Congress made money trading ISRG?

8 members of Congress have disclosed buying ISRG in the last 5 years, 16 purchases in total. Measured over the 12 months after each trade date, the median purchase returned +20.1% against +21.4% for SPY over the same windows, and 8 of the 16 (50%) beat the index. These are not returns anyone actually earned: congressional disclosures report a dollar bracket and no share count, so each purchase is counted once and weighted equally, and later sales are not matched back to the buys that opened them.

Where can I see ISRG SEC filings?

Recent filings are listed on this page, newest first. The latest is a 10-Q filed October 21, 2026.

Data on this page comes from SEC EDGAR, public disclosure feeds and market data providers, and may be delayed or incomplete. Nothing here is investment advice.